Home | Memorial Sloan Kettering Cancer Center Library

ONESEARCH

Top Databases	Popular Journals	Key Services
CINAHL Cochrane Library EMBASE Scopus Web of Science See all	Blood JAMA Oncology JCO Nature Science See all	ILLiad Document Delivery Reference & Consultation Systematic Review Learning Lab Research Data Management See all

Announcement

Our User Community can enter the Library on Mondays and Thursdays from 8:30 am to 5:00 pm (12:30 pm to 1:00 pm closed for additional cleaning of user workstations).

All MSK Staff must register for their user workstation in advance at: https://mskcc.libcal.com/spaces.
Additional info: Reopening Guidelines & Procedures

The MSK User Community can access the majority of the Library's services and collections remotely. Visit our Virtual Library Services page to learn more.

Looking for information about COVID-19? Visit our post on the MSK Library Blog to browse vetted resources and sites.

News & Events

The Library has compiled a list of helpful sources for COVID-19 information on our blog. Need additional COVID-related literature or resources? Ask Us!
MSK will soon be upgrading to EndNote desktop version 20. Check out this fun video of the “Evolution of EndNote desktop” and learn how version 20 differs from X9.
January is Cervical Cancer Awareness Month. Learn about prevention and risk factors, screening, diagnosis, living with cervical cancer, and more from MSK cervical cancer experts.
MSK's Food to Overcome Disparities (FOOD) Program operates 12 pantries co-located in cancer clinics serving patients across NYC. Learn more about supporting the FOOD Program this holiday season.
We are saddened by the loss of Kathryn Anderson, PhD, former head of the MSK Kathryn Anderson Lab. Her legacy will live on through her groundbreaking cancer research and her memory as a wonderful and generous colleague.

LibGuides

Evidence-Based Practice

Defining PICO & related info

NIH Public Access Policy

Info & guidance for complying

Nursing Resources

eJournals and Websites

See all

Today's Science Sparks

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. Fig. 1. Durvalumab plus tremelimumab combination therapy with or without paclitaxel administration schedule.

Boileve A, Hilmi M, Gougis P, Cohen R, Rousseau B, Blanc JF, Ben Abdelghani M, Castanie H, Dahan L, Tougeron D, Metges JP, Tournigand C, Garcia-Larnicol ML, Vernerey D, Turpin A, Neuzillet C

Learn more

View the Sparks archives

Synapse